# Urinary Excretion of Acetylamantadine by Cancer Patients

> **NCT00755898** · PHASE2 · COMPLETED · sponsor: **University of Manitoba** · enrollment: 150 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Ingestion of a 200 mg dose of amantadine hydrochloride
- **DRUG:** Ingestion of a 200 mg dose of amantadine hydrochloride

## Key facts

- **NCT ID:** NCT00755898
- **Lead sponsor:** University of Manitoba
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-07
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-11-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755898, "Urinary Excretion of Acetylamantadine by Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00755898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*